Skip to main content
Top
Published in: BMC Nephrology 1/2024

Open Access 01-12-2024 | Acute Kidney Injury | Research

Kidney replacement and conservative therapies in rhabdomyolysis: a retrospective analysis

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Background

Toxic renal effects of myoglobin following rhabdomyolysis can cause acute kidney injury (AKI) with the necessity of kidney replacement therapy (KRT). Fast elimination of myoglobin seems notable to save kidney function and intensify kidney repair. Clinical data regarding efficacy of KRT in critical care patients with rhabdomyolysis and AKI are limited. This retrospective analysis aimed to identify differences between conservative therapy and different modalities of KRT regarding myoglobin elimination and clinical outcome.

Methods

This systematic, retrospective, single-center study analyzed 328 critical care patients with rhabdomyolysis (myoglobin > 1000 µg/l). Median reduction rate of myoglobin after starting KRT was calculated and compared for different modalities. Multivariate logistic regression models were established to identify potential confounder on hospital mortality. Filter lifetime of the various extracorporeal circuits was analyzed by Kaplan–Meier curves.

Results

From 328 included patients 171 required KRT. Health condition at admission of this group was more critical compared to patient with conservative therapy. Myoglobin reduction rate did not differ between the groups (KRT 49% [30.8%; 72.2%] vs. conservative treatment (CT) 61% [38.5%; 73.5%]; p = 0.082). Comparison between various extracorporeal procedures concerning mortality showed no significant differences. Hospital mortality was 55.6% among patients with KRT and 18.5% with CT (p < 0.001). Multivariate logistic regression model identified requirement for KRT (OR: 2.163; CI: 1.061–4.407); p = 0.034) and the SOFA Score (OR: 1.111; CI: 1.004–1.228; p = 0.041) as independent predictive factors for hospital mortality. When comparing specific KRT using multivariate regression, no benefit was demonstrated for any treatment modality. Life span of the extracorporeal circuit was shorter with CVVH compared to that of others (log-Rank p = 0.017).

Conclusions

This study emphasizes that AKI requiring KRT following rhabdomyolysis is accompanied by high mortality rate. Differences in myoglobin reduction rate between various KRTs could not be confirmed, but CVVH was associated with reduced filter lifetime compared to other KRTs, which enable myoglobin elimination, too.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet (London, England). 2019;394(10212):1949–64.PubMedCrossRef Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet (London, England). 2019;394(10212):1949–64.PubMedCrossRef
2.
go back to reference Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411–23.PubMedCrossRef Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411–23.PubMedCrossRef
3.
go back to reference Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–8.PubMedCrossRef Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–8.PubMedCrossRef
4.
go back to reference Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.PubMedPubMedCentralCrossRef Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.PubMedPubMedCentralCrossRef
5.
go back to reference Gameiro J, Marques F, Lopes JA. Long-term consequences of acute kidney injury: a narrative review. Clin Kidney J. 2021;14(3):789–804.PubMedCrossRef Gameiro J, Marques F, Lopes JA. Long-term consequences of acute kidney injury: a narrative review. Clin Kidney J. 2021;14(3):789–804.PubMedCrossRef
6.
go back to reference Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.PubMedCrossRef Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.PubMedCrossRef
7.
go back to reference Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis - An overview for clinicians. Crit Care. 2005;9(2):158–69.PubMedCrossRef Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis - An overview for clinicians. Crit Care. 2005;9(2):158–69.PubMedCrossRef
8.
go back to reference Panizo N, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, Moreno JA. Molecular mechanisms and novel therapeutic approaches to rhabdomyolysis-induced acute kidney injury. Kidney Blood Press Res. 2015;40(5):520–32.PubMedCrossRef Panizo N, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, Moreno JA. Molecular mechanisms and novel therapeutic approaches to rhabdomyolysis-induced acute kidney injury. Kidney Blood Press Res. 2015;40(5):520–32.PubMedCrossRef
9.
go back to reference Amyot SL, Leblanc M, Thibeault Y, Geadah D, Cardinal J. Myoglobin clearance and removal during continuous venovenous hemofiltration. Intensive Care Med. 1999;25(10):1169–72.PubMedCrossRef Amyot SL, Leblanc M, Thibeault Y, Geadah D, Cardinal J. Myoglobin clearance and removal during continuous venovenous hemofiltration. Intensive Care Med. 1999;25(10):1169–72.PubMedCrossRef
10.
go back to reference Zhang L, Kang Y, Fu P, Cao Y, Shi Y, Liu F, et al. Myoglobin clearance by continuous venous-venous haemofiltration in rhabdomyolysis with acute kidney injury: A case series. Injury. 2012;43(5):619–23.PubMedCrossRef Zhang L, Kang Y, Fu P, Cao Y, Shi Y, Liu F, et al. Myoglobin clearance by continuous venous-venous haemofiltration in rhabdomyolysis with acute kidney injury: A case series. Injury. 2012;43(5):619–23.PubMedCrossRef
11.
go back to reference Naka T, Jones D, Baldwin I, Fealy N, Bates S, Goehl H, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care. 2005;9(2):R90–5.PubMedPubMedCentralCrossRef Naka T, Jones D, Baldwin I, Fealy N, Bates S, Goehl H, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care. 2005;9(2):R90–5.PubMedPubMedCentralCrossRef
12.
go back to reference Weidhase L, de Fallois J, Haußig E, Kaiser T, Mende M, Petros S. Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial. Crit Care. 2020;24(1):644.PubMedPubMedCentralCrossRef Weidhase L, de Fallois J, Haußig E, Kaiser T, Mende M, Petros S. Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial. Crit Care. 2020;24(1):644.PubMedPubMedCentralCrossRef
13.
go back to reference Mikkelsen TS, Toft P. Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis. Acta Anaesthesiol Scand. 2005;49(6):859–64.PubMedCrossRef Mikkelsen TS, Toft P. Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis. Acta Anaesthesiol Scand. 2005;49(6):859–64.PubMedCrossRef
14.
go back to reference Heyne N, Guthoff M, Krieger J, Haap M, Häring HU. High cut-off renal replacement therapy for removal of myoglobin in severe rhabdomyolysis and acute kidney injury: a case series. Nephron Clin Pract. 2012;121(3–4):c159–64.PubMed Heyne N, Guthoff M, Krieger J, Haap M, Häring HU. High cut-off renal replacement therapy for removal of myoglobin in severe rhabdomyolysis and acute kidney injury: a case series. Nephron Clin Pract. 2012;121(3–4):c159–64.PubMed
15.
go back to reference Weidhase L, Haussig E, Haussig S, Kaiser T, de Fallois J, Petros S. Middle molecule clearance with high cut-off dialyzer versus high-flux dialyzer using continuous veno-venous hemodialysis with regional citrate anticoagulation: A prospective randomized controlled trial. Isaka Y, editor. PLoS One. 2019;14(4):e0215823.PubMedPubMedCentralCrossRef Weidhase L, Haussig E, Haussig S, Kaiser T, de Fallois J, Petros S. Middle molecule clearance with high cut-off dialyzer versus high-flux dialyzer using continuous veno-venous hemodialysis with regional citrate anticoagulation: A prospective randomized controlled trial. Isaka Y, editor. PLoS One. 2019;14(4):e0215823.PubMedPubMedCentralCrossRef
16.
go back to reference Goubella A, Gankam-Kengne F, Baudoux T, Fagnoul D, Husson C, Delforge ML, et al. Severe myoglobinuric acute kidney injury in a kidney recipient: rapid recovery after hemodialysis with the super high-flux membrane Theralite®. Clin Nephrol. 2017;88(12):359–63.PubMedCrossRef Goubella A, Gankam-Kengne F, Baudoux T, Fagnoul D, Husson C, Delforge ML, et al. Severe myoglobinuric acute kidney injury in a kidney recipient: rapid recovery after hemodialysis with the super high-flux membrane Theralite®. Clin Nephrol. 2017;88(12):359–63.PubMedCrossRef
17.
go back to reference Premru V, Kovač J, Buturović-Ponikvar J, Ponikvar R. High cut-off membrane hemodiafiltration in myoglobinuric acute renal failure: a case series. Ther Apher Dial. 2011;15(3):287–91.PubMedCrossRef Premru V, Kovač J, Buturović-Ponikvar J, Ponikvar R. High cut-off membrane hemodiafiltration in myoglobinuric acute renal failure: a case series. Ther Apher Dial. 2011;15(3):287–91.PubMedCrossRef
18.
go back to reference Dilken O, Ince C, van der Hoven B, Thijsse S, Ormskerk P, De Geus HRH. Successful reduction of creatine kinase and myoglobin levels in severe rhabdomyolysis using extracorporeal blood purification (CytoSorb®). Blood Purif. 2020;49:743–7.PubMedCrossRef Dilken O, Ince C, van der Hoven B, Thijsse S, Ormskerk P, De Geus HRH. Successful reduction of creatine kinase and myoglobin levels in severe rhabdomyolysis using extracorporeal blood purification (CytoSorb®). Blood Purif. 2020;49:743–7.PubMedCrossRef
19.
go back to reference Kousoulas L, Wittel U, Fichtner-Feigl S, Utzolino S. Hemoadsorption in a case of severe septic shock and necrotizing fasciitis caused by nontraumatic renal rupture due to pyelonephritis with obstructive uropathy. Case reports Crit care. 2018;2018:5248901.CrossRef Kousoulas L, Wittel U, Fichtner-Feigl S, Utzolino S. Hemoadsorption in a case of severe septic shock and necrotizing fasciitis caused by nontraumatic renal rupture due to pyelonephritis with obstructive uropathy. Case reports Crit care. 2018;2018:5248901.CrossRef
20.
go back to reference Scharf C, Liebchen U, Paal M, Irlbeck M, Zoller M, Schroeder I. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit Care. 2021;25(1):41.PubMedPubMedCentralCrossRef Scharf C, Liebchen U, Paal M, Irlbeck M, Zoller M, Schroeder I. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit Care. 2021;25(1):41.PubMedPubMedCentralCrossRef
21.
go back to reference Albrecht F, Schunk S, Fuchs M, Volk T, Geisel J, Fliser D, et al. Rapid and effective elimination of myoglobin with CytoSorb® hemoadsorber in patients with severe rhabdomyolysis. Blood Purif. 2023;2:1–8. Albrecht F, Schunk S, Fuchs M, Volk T, Geisel J, Fliser D, et al. Rapid and effective elimination of myoglobin with CytoSorb® hemoadsorber in patients with severe rhabdomyolysis. Blood Purif. 2023;2:1–8.
22.
go back to reference El-Abdellati E, Eyselbergs M, Sirimsi H, van Hoof V, Wouters K, Verbrugghe W, et al. An observational study on rhabdomyolysis in the intensive care unit exploring its risk factors and main complication: Acute kidney injury. Ann Intensive Care. 2013;3(1):1–8.CrossRef El-Abdellati E, Eyselbergs M, Sirimsi H, van Hoof V, Wouters K, Verbrugghe W, et al. An observational study on rhabdomyolysis in the intensive care unit exploring its risk factors and main complication: Acute kidney injury. Ann Intensive Care. 2013;3(1):1–8.CrossRef
23.
go back to reference Kasaoka S, Todani M, Kaneko T, Kawamura Y, Oda Y, Tsuruta R, et al. Peak value of blood myoglobin predicts acute renal failure induced by rhabdomyolysis. J Crit Care. 2010;25(4):601–4.PubMedCrossRef Kasaoka S, Todani M, Kaneko T, Kawamura Y, Oda Y, Tsuruta R, et al. Peak value of blood myoglobin predicts acute renal failure induced by rhabdomyolysis. J Crit Care. 2010;25(4):601–4.PubMedCrossRef
24.
25.
go back to reference Sever MS, Vanholder R, RDRTF of ISN Work Group on Recommendations for the Management of Crush Victims in Mass Disasters. Recommendation for the management of crush victims in mass disasters. Nephrol Dial Transplant. 2012;27(Suppl 1):i1–67.PubMedCrossRef Sever MS, Vanholder R, RDRTF of ISN Work Group on Recommendations for the Management of Crush Victims in Mass Disasters. Recommendation for the management of crush victims in mass disasters. Nephrol Dial Transplant. 2012;27(Suppl 1):i1–67.PubMedCrossRef
26.
go back to reference Shigemoto T, Rinka H, Matsuo Y, Kaji A, Tsukioka K, Ukai T, et al. Blood purification for crush syndrome. Ren Fail. 1997;19(5):711–9.PubMedCrossRef Shigemoto T, Rinka H, Matsuo Y, Kaji A, Tsukioka K, Ukai T, et al. Blood purification for crush syndrome. Ren Fail. 1997;19(5):711–9.PubMedCrossRef
28.
go back to reference STARRT-AKI Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Canadian Nephrology Trials Network, Irish Critical Care Trials Group, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383(3):240–51.CrossRef STARRT-AKI Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Canadian Nephrology Trials Network, Irish Critical Care Trials Group, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383(3):240–51.CrossRef
29.
go back to reference Fayad AI, Buamscha DG, Ciapponi A. ntensity of continuous renal replacement therapy for acute kidney injury. In: Fayad AI, editor. Cochrane database of systematic reviews. Chichester: John Wiley & Sons, Ltd; 2013. Fayad AI, Buamscha DG, Ciapponi A. ntensity of continuous renal replacement therapy for acute kidney injury. In: Fayad AI, editor. Cochrane database of systematic reviews. Chichester: John Wiley & Sons, Ltd; 2013.
30.
go back to reference Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754–8.PubMedCrossRef Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754–8.PubMedCrossRef
31.
go back to reference Beck DH, Smith GB, Pappachan JV, Millar B. External validation of the SAPS II, APACHE II and APACHE III prognostic models in South England: a multicentre study. Intensive Care Med. 2003;29(2):249–56.PubMedCrossRef Beck DH, Smith GB, Pappachan JV, Millar B. External validation of the SAPS II, APACHE II and APACHE III prognostic models in South England: a multicentre study. Intensive Care Med. 2003;29(2):249–56.PubMedCrossRef
32.
go back to reference Tang W, Chen Z, Wu W, Qiu H, Bo H, Zhang L, et al. Renal protective effects of early continuous venovenous hemofiltration in rhabdomyolysis: improved renal mitochondrial dysfunction and inhibited apoptosis. Artif Organs. 2013;37(4):390–400.PubMedCrossRef Tang W, Chen Z, Wu W, Qiu H, Bo H, Zhang L, et al. Renal protective effects of early continuous venovenous hemofiltration in rhabdomyolysis: improved renal mitochondrial dysfunction and inhibited apoptosis. Artif Organs. 2013;37(4):390–400.PubMedCrossRef
33.
34.
go back to reference Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20(1):135.PubMedPubMedCentralCrossRef Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20(1):135.PubMedPubMedCentralCrossRef
35.
go back to reference Vangstad M, Bjornaas MA, Jacobsen D. Rhabdomyolysis: a 10-year retrospective study of patients treated in a medical department. Eur J Emerg Med. 2019;26(3):199–204.PubMedCrossRef Vangstad M, Bjornaas MA, Jacobsen D. Rhabdomyolysis: a 10-year retrospective study of patients treated in a medical department. Eur J Emerg Med. 2019;26(3):199–204.PubMedCrossRef
36.
go back to reference Candela N, Silva S, Georges B, Cartery C, Robert T, Moussi-Frances J, et al. Short- and long-term renal outcomes following severe rhabdomyolysis: a French multicenter retrospective study of 387 patients. Ann Intensive Care. 2020;10(1):27.PubMedPubMedCentralCrossRef Candela N, Silva S, Georges B, Cartery C, Robert T, Moussi-Frances J, et al. Short- and long-term renal outcomes following severe rhabdomyolysis: a French multicenter retrospective study of 387 patients. Ann Intensive Care. 2020;10(1):27.PubMedPubMedCentralCrossRef
37.
go back to reference Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442–8.PubMedCrossRef Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442–8.PubMedCrossRef
38.
go back to reference Simpson JP, Taylor A, Sudhan N, Menon DK, Lavinio A. Rhabdomyolysis and acute kidney injury: Creatine kinase as a prognostic marker and validation of the McMahon Score in a 10-year cohort: A retrospective observational evaluation. Eur J Anaesthesiol. 2016;33(12):906–12.PubMedCrossRef Simpson JP, Taylor A, Sudhan N, Menon DK, Lavinio A. Rhabdomyolysis and acute kidney injury: Creatine kinase as a prognostic marker and validation of the McMahon Score in a 10-year cohort: A retrospective observational evaluation. Eur J Anaesthesiol. 2016;33(12):906–12.PubMedCrossRef
39.
go back to reference Baeza-Trinidad R, Brea-Hernando A, Morera-Rodriguez S, Brito-Diaz Y, Sanchez-Hernandez S, El Bikri L, et al. Creatinine as predictor value of mortality and acute kidney injury in rhabdomyolysis. Intern Med J. 2015;45(11):1173–8.PubMedCrossRef Baeza-Trinidad R, Brea-Hernando A, Morera-Rodriguez S, Brito-Diaz Y, Sanchez-Hernandez S, El Bikri L, et al. Creatinine as predictor value of mortality and acute kidney injury in rhabdomyolysis. Intern Med J. 2015;45(11):1173–8.PubMedCrossRef
40.
go back to reference Xiao L, Ran X, Zhong Y, Le Y, Li S. Serum creatine kinase levels are not associated with an increased need for continuous renal replacement therapy in patients with acute kidney injury following rhabdomyolysis. Ren Fail. 2022;44(1):893–901.PubMedPubMedCentralCrossRef Xiao L, Ran X, Zhong Y, Le Y, Li S. Serum creatine kinase levels are not associated with an increased need for continuous renal replacement therapy in patients with acute kidney injury following rhabdomyolysis. Ren Fail. 2022;44(1):893–901.PubMedPubMedCentralCrossRef
41.
go back to reference Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–29.PubMedCrossRef Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–29.PubMedCrossRef
42.
go back to reference Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317(3):290–300.PubMedCrossRef Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317(3):290–300.PubMedCrossRef
43.
45.
go back to reference Kim HW, Kim S, Ohn JH, Kim NH, Lee J, Kim ES, et al. Role of bicarbonate and volume therapy in the prevention of acute kidney injury in rhabdomyolysis: a retrospective propensity score-matched cohort study. Kidney Res Clin Pract. 2022;41(3):310–21.PubMedCrossRef Kim HW, Kim S, Ohn JH, Kim NH, Lee J, Kim ES, et al. Role of bicarbonate and volume therapy in the prevention of acute kidney injury in rhabdomyolysis: a retrospective propensity score-matched cohort study. Kidney Res Clin Pract. 2022;41(3):310–21.PubMedCrossRef
46.
go back to reference Sorrentino SA, Kielstein JT, Lukasz A, Sorrentino JN, Gohrbandt B, Haller H, et al. High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Crit Care Med. 2011;39(1):184–6.PubMedCrossRef Sorrentino SA, Kielstein JT, Lukasz A, Sorrentino JN, Gohrbandt B, Haller H, et al. High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Crit Care Med. 2011;39(1):184–6.PubMedCrossRef
47.
go back to reference Jerman A, Andonova M, Persic V, Gubensek J. Extracorporeal removal of myoglobin in patients with rhabdomyolysis and acute kidney injury: comparison of high and medium cut-off membrane and an adsorber cartridge. Blood Purif. 2022;51(11):907–11.PubMedCrossRef Jerman A, Andonova M, Persic V, Gubensek J. Extracorporeal removal of myoglobin in patients with rhabdomyolysis and acute kidney injury: comparison of high and medium cut-off membrane and an adsorber cartridge. Blood Purif. 2022;51(11):907–11.PubMedCrossRef
48.
go back to reference Mariano F, Mella A, Rumbolo F, Holló Z, Bergamo D, Congiu G, Mengozzi G, Berardino M, Stella M, Biancone L. Clearance of NT-proBNP and procalcitonin during continuous venovenous hemodialysis with the medium cutoff filter in patients with rhabdomyolysis-associated early acute kidney injury. Blood Purif. 2023;52(5):446–54.PubMedCrossRef Mariano F, Mella A, Rumbolo F, Holló Z, Bergamo D, Congiu G, Mengozzi G, Berardino M, Stella M, Biancone L. Clearance of NT-proBNP and procalcitonin during continuous venovenous hemodialysis with the medium cutoff filter in patients with rhabdomyolysis-associated early acute kidney injury. Blood Purif. 2023;52(5):446–54.PubMedCrossRef
49.
go back to reference Liu C, Mao Z, Kang H, Hu J, Zhou F. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: A meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care. 2016;20(1):1–13.CrossRef Liu C, Mao Z, Kang H, Hu J, Zhou F. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: A meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care. 2016;20(1):1–13.CrossRef
50.
go back to reference Bai M, Zhou M, He L, Ma F, Li Y, Yu Y, et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med. 2015;41(12):2098–110.PubMedCrossRef Bai M, Zhou M, He L, Ma F, Li Y, Yu Y, et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med. 2015;41(12):2098–110.PubMedCrossRef
51.
go back to reference Zarbock A, Küllmar M, Kindgen-Milles D, Wempe C, Gerss J, Brandenburger T, et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA. 2020;324(16):1629–39.PubMedCrossRef Zarbock A, Küllmar M, Kindgen-Milles D, Wempe C, Gerss J, Brandenburger T, et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA. 2020;324(16):1629–39.PubMedCrossRef
52.
go back to reference Ricci Z, Ronco C, Bachetoni A, D’amico G, Rossi S, Alessandri E, et al. Solute removal during continuous renal replacement therapy in critically ill patients: Convection versus diffusion. Crit Care. 2006;10(2):1–7.CrossRef Ricci Z, Ronco C, Bachetoni A, D’amico G, Rossi S, Alessandri E, et al. Solute removal during continuous renal replacement therapy in critically ill patients: Convection versus diffusion. Crit Care. 2006;10(2):1–7.CrossRef
53.
go back to reference Brain M, Winson E, Roodenburg O, McNeil J. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 2017;18(1):69.PubMedPubMedCentralCrossRef Brain M, Winson E, Roodenburg O, McNeil J. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 2017;18(1):69.PubMedPubMedCentralCrossRef
54.
go back to reference Aslan G, Afsar B, Sag AA, Camkiran V, Erden N, Yilmaz S, et al. The effect of urine pH and urinary uric acid levels on the development of contrast nephropathy. Kidney Blood Press Res. 2020;45(1):131–41.PubMedCrossRef Aslan G, Afsar B, Sag AA, Camkiran V, Erden N, Yilmaz S, et al. The effect of urine pH and urinary uric acid levels on the development of contrast nephropathy. Kidney Blood Press Res. 2020;45(1):131–41.PubMedCrossRef
55.
go back to reference Reeder BJ, Wilson MT. The effects of pH on the mechanism of hydrogen peroxide and lipid hydroperoxide consumption by myoglobin: a role for the protonated ferryl species. Free Radic Biol Med. 2001;30(11):1311–8.PubMedCrossRef Reeder BJ, Wilson MT. The effects of pH on the mechanism of hydrogen peroxide and lipid hydroperoxide consumption by myoglobin: a role for the protonated ferryl species. Free Radic Biol Med. 2001;30(11):1311–8.PubMedCrossRef
Metadata
Title
Kidney replacement and conservative therapies in rhabdomyolysis: a retrospective analysis
Publication date
01-12-2024
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-024-03536-8

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.